P323: Beyond REMS: A Real-World Data and Community Surveillance Approach to Adaptive Opioid Regulation
Poster Presenter
Aysha Rana
Regulatory Affairs Specialist
Spectra Medical/Northeastern University United States
Objectives
To propose a next-generation opioid regulatory framework that integrates real-world data (RWD), adaptive licensing, pharmacist-led surveillance, and community-driven harm reduction to enhance public health responsiveness and regulatory flexibility.
Method
The study analyzed opioid regulatory policies (2012-2024) in the US, reviewed FDA Sentinel & CDC SDOH data, and modeled risk prediction using machine learning. Pharmacist-led reporting systems and harm reduction data were also evaluated for integration into the framework.
Results
Data from FDA Sentinel, CDC SVI, and published opioid surveillance reports (2012-2024) were analyzed. Combining real-world data (RWD) with social determinants of health (SDOH) improved the accuracy of predicting opioid misuse hotspots by 27% compared to traditional REMS and PDMP systems.
When pharmacist-reported adverse events were added through a simulated blockchain-based reporting system, the time to detect emerging misuse signals was reduced by 30%.
The study confirmed that static systems like REMS are too slow to respond to fast-changing opioid risks. In contrast, this proposed framework—linking adaptive licensing, real-time surveillance, and community harm reduction data—enables faster label updates, earlier interventions, and better-targeted resources.
The findings support the hypothesis that a dynamic, data-driven regulatory process enhances public health protection while aligning with Pharma 4.0 goals of continuous learning and digital innovation.
Conclusion
This study concludes that static approaches like REMS are insufficient to manage the rapidly evolving opioid crisis. By combining real-world data, pharmacist-led surveillance, and community harm reduction insights, regulatory decisions can become faster, smarter, and more adaptive. This real-time framework ensures that opioid labels and prescribing guidelines continuously reflect emerging risks, particularly in high-vulnerability communities identified through social determinants of health data. The proposed model aligns with Pharma 4.0 principles, promoting digital innovation and continuous learning across regulatory processes. With faster risk detection and more equitable interventions, this adaptive approach offers a scalable blueprint for regulating other high-risk medications, ultimately strengthening public health protection while preserving access to necessary therapies.
